Compare CELC & LFST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CELC | LFST |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.8B |
| IPO Year | 2017 | 2021 |
| Metric | CELC | LFST |
|---|---|---|
| Price | $53.29 | $13.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 11 |
| Target Price | ★ $150.85 | $16.80 |
| AVG Volume (30 Days) | 920.9K | ★ 6.2M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,424,285,000.00 |
| Revenue This Year | N/A | $22.65 |
| Revenue Next Year | $1,921.71 | $13.62 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 13.85 |
| 52 Week Low | $53.54 | $6.21 |
| 52 Week High | $151.02 | $15.66 |
| Indicator | CELC | LFST |
|---|---|---|
| Relative Strength Index (RSI) | 30.06 | 52.01 |
| Support Level | N/A | $11.73 |
| Resistance Level | $72.76 | $14.15 |
| Average True Range (ATR) | 4.24 | 0.82 |
| MACD | -1.03 | -0.10 |
| Stochastic Oscillator | 0.16 | 20.99 |
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family, and group therapy. It treats a broad range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder, using evidence-based approaches to ensure effective treatment. The group has a single operating and reportable segment of mental health services.